Gilder Gagnon Howe & Co’s Roivant Sciences ROIV Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$898K	Buy	+25,365	New	+$750K	0.01%	250
2026 Q1	–	Sell	-483,117	Closed	-$10.5M	–	272
2025 Q4	$10.5M	Sell	483,117 -12,840	-3%	-$253K	0.11%	113
2025 Q3	$7.5M	Sell	495,957 -51,883	-9%	-$642K	0.08%	130
2025 Q2	$6.17M	Sell	547,840 -547,030	-50%	-$5.93M	0.07%	133
2025 Q1	$11M	Sell	1,094,870 -68,116	-6%	-$737K	0.14%	101
2024 Q4	$13.8M	Buy	+1,162,986	New	+$13.7M	0.15%	102

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Gilder Gagnon Howe & Co's ROIV Position: Q2 2026 in Review

Gilder Gagnon Howe & Co opened a new position in Roivant Sciences (ROIV) in Q2 2026: 25,365 shares worth $898K. The stake represents 0.01% of the portfolio and ranks #250 among its holdings. This is a return to the name: Gilder Gagnon Howe & Co previously reported a position in ROIV as recently as Q4 2025.

Gilder Gagnon Howe & Co first reported a position in ROIV in Q4 2024 and has held it in 6 quarters since. The position peaked at $13.8M in Q4 2024. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Gilder Gagnon Howe & Co held 25,365 shares of Roivant Sciences worth $898K as of Q2 2026.
Roivant Sciences was a new Gilder Gagnon Howe & Co position in Q2 2026.
Roivant Sciences made up 0.01% of Gilder Gagnon Howe & Co's portfolio in Q2 2026, its #250 holding.
Gilder Gagnon Howe & Co first reported a position in Roivant Sciences in Q4 2024 and has held it in 6 quarters since.
Gilder Gagnon Howe & Co's Roivant Sciences position peaked at $13.8M in Q4 2024.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.